Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cogent Biosciences, Inc. - Common Stock (NQ:COGT)

16.20 +1.07 (+7.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cogent Biosciences, Inc. - Common Stock

< Previous 1 2 3 Next >
Cogent Biosciences Soars to 52-Week High on "Breakthrough" Systemic Mastocytosis Trial Results
Cogent Biosciences (NASDAQ: COGT) experienced a dramatic surge in its stock price, hitting a 52-week high in early July 2025, following the announcement of highly positive "breakthrough results" from... 
Via MarketMinute
Topics Economy Supply Chain
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags
According to the technical analysis of over 4,400 firms with a market cap exceeding $100 million, three firms are in the overbought zone. 
Via Benzinga
Why Is Cogent Biosciences Stock Trading Higher On Monday?
Cogent Biosciences' SUMMIT trial shows bezuclastinib improves symptoms and quality of life in systemic mastocytosis, with favorable safety data. 
Via Benzinga
Cogent Biosciences Inc. (NASDAQ: COGT) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Analyst Expectations for Cogent Biosciences's Future
 
Via Benzinga
Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges
Bezuclastinib met all primary and secondary endpoints in a Phase 3 trial for non-advanced systemic mastocytosis, with analysts highlighting strong efficacy, safety, and commercial potential. 
Via Stocktwits
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst
Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025. 
Via Benzinga
US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As 'Durable Drivers Of Returns'
U.S. stock futures were fluctuating on Tuesday after trimming gains on Monday. Futures of major benchmark indices were trading mixed. 
Via Benzinga
Topics Artificial Intelligence Government
Trump Tariffs Sink Dow Over 400 Points: Investor Sentiment Declines, But Fear & Greed Index Remains In 'Extreme Greed' Zone
 
Via Benzinga
Topics Government Stocks
Dow Dips 1%; Mustang Bio Shares Spike Higher
 
Via Benzinga
Topics Stocks
Let's uncover which stocks are experiencing notable gaps during today's session.
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Why Is Cogent Biosciences Stock Trading Higher On Monday?
Cogent reported positive SUMMIT trial data for bezuclastinib in NonAdvSM and plans to file for FDA approval by late 2025. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
COGT Stock Earnings: Cogent Biosciences Misses EPS for Q2 2024
COGT stock results show that Cogent Biosciences missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024
COGT stock results show that Cogent Biosciences missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Nasdaq Edges Higher; Macy's Shares Jump
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&P... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Dow Surges 100 Points; Cogent Biosciences Shares Plunge
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.28% to 36,349.22 while the NASDAQ fell 0.36% to 14,352.34. The S&P... 
Via Benzinga
Topics Stocks
Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment
Cogent Biosciences Inc (NASDAQ: COGT) shared data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) at the American Society... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.